Azure Power Global Limited
Azure Power Global Limited (NYSE: AZRE) is an independent power producer, which sells solar electricity on long-term fixed-price contracts.
Investment Rationale – SELL at USD 23.72
- The stock has given a remarkable +48.53% growth in the last one year.
- The cost of operations increased by 16% during Q4 FY21, and subsequently, the Company reported significant net losses.
- From a technical standpoint, AZRE’s stock price is sustaining below the 100-day EMA (USD 25.53), reflecting a bearish momentum. Meanwhile, the momentum oscillator 14-day RSI (56.15) is moving towards the overbought position at the current levels.
- In the past six months, the stock price has shown a significant underperformance against the NYSE Composite index by delivering a negative ~34.91% return.
Risk Assessments
- Inflationary pressure can impact material and commodity prices.
- The change in tariffs and another potential wave of the Covid-19 pandemic can lead to project delays and create supply-related challenges.
- It has a limited operating history and relatively a new public entity.
Recent News
Disposal: On 5 April 2021, AZRE sold its non-core solar rooftop portfolio to Radiance Renewables Pvt Ltd, to improve the overall cost structure.
Financial Highlights (for the fourth quarter ended 31 March 2021, as on 15 June 2021)
(Source: Company Website)
- During Q4 FY21, AZRE reported 16% year-on-year increase in the operating revenue; however, adverse weather conditions continued to impact the cost of operations.
- The net loss for Q4 FY21, AZRE stood at US$ 38.1 million since results were impacted by the impairment loss on assets.
- The Non-GAAP cash flow to equity reported a 55% year-on-year increase in Q4 FY21.
Share Price Chart
(Analysis done by Kalkine Group)
Valuation Methodology: EV/Sales Approach (FY22) (Illustrative)
Conclusion
Although the Company reported an increase in revenues and adjusted EBITDA during Q4 FY21, higher finance cost and impairment loss led to net loss for the Company. Moreover, the uncertainties pertinent to Covid-19 disruption is persisting. Moreover, as we are able to achieve our short-term upside target, it is better to liquidate at current level and will wait for a fresh technical level or growth catalyst to re-evaluate our stance in the short term. The stock made a 52 week High and Low of USD 53.60 and USD 15.16, respectively.
Based on the uncertain outlook, history of losses, challenging market conditions, with support from unfavourable valuation conducted above, we have given a “SELL” stance on Azure Power Global Limited at the closing price of USD 23.72 (as on 24 June 2021).
Arcturus Therapeutics Inc
Arcturus Therapeutics Inc (NASDAQ: ARCT) is a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within the liver and rare respiratory diseases.
Investment Highlights – Arcturus Therapeutics Inc – SELL at USD 34.32
- ARCT majorly depends on the revenue from licenses and collaborative payments received for R&D, which does not guarantee long term revenues in case the Company faces any hiccups in the trials.
- The collaborated revenue and net loss had demonstrated a downward trend during Q1 FY21 as compared to Q1 FY20.
- The consensus estimates indicated that the Company would remain loss-making for the remaining quarters of 2021.
- From a technical standpoint, 50-day EMA (~USD 34.90) seems unfavourable and resist the upside potential in the stock price.
Key Risks
- Because license payments account for the majority of ARCT's revenue, any disruption or conflicts with its key partners might have a significant impact on the company's top line as well as the liquidity needed to sustain future studies.
- The company operates in a strict regulatory industry, and any change in regulations or policies could affect the overall business.
- The company's future is contingent on clinical trials and FDA approvals, and any delay could result in higher costs and a delay in income generation.
Q1 FY21 Financial Highlights (for three months ended 31 March 2021, as of 13 May 2021)
(Source: Company result)
- The Company had reported revenue of USD 2.1 million during Q1 FY21 against USD 2.6 million in the three months ended 31 March 2020.
- The R&D expenses increased by approximately USD 42.1 million on a YoY basis and USD 25.8 million on a QoQ basis.
- Operating expenses increased significantly to USD 59.8 million for the three months ended 31 March 2021, compared to USD 12.1 million for the three months ended 31 March 2020.
- The Company was able to maintain the cash balance at USD 466.9 million as of 31 March 2021, against cash and cash equivalents of USD 463.0 million in the previous quarter.
One Year Share Price Chart
(Analysis done by Kalkine Group)
Conclusion
The Company has made accelerated progress towards the advancement of its clinical pipelines, but they still have a long road ahead. The management of the company remains optimistic on approval for ARCT-021, a differentiated mRNA vaccine candidate targeting COVID-19 which could become the preferred vaccine for Covid-19. The company now focuses on the liver and lung mRNA pipeline programs which could potentially be another major revenue driver for the company. The stock made a 52 week High and Low of USD 129.71 and USD 24.87, respectively.
Based on the negligible top-line business and weak profitability levels, we have given a "SELL" stance on Arcturus Therapeutics Inc at the closing market price of USD 34.32 (as of 24 June 2021), while we will suggest fresh buying when the Company turns profitable.
*The reference data in this report has been partly sourced from REFINITIV.
*All forecasted figures and Peer information have been taken from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.